Elizabeth S. Gabitzsch

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

Michael A. Morse, Arvind Chaudhry, Elizabeth S. Gabitzsch et al. · Cancer Immunology Immunotherapy · 2013 · 90 citations · Full text

Cancer Immunosurveillance, Anti-adenoviral Neutralizing Antibodies, Immunology +9

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression

Adrian E. Rice, Yvette Latchman, Joseph P. Balint et al. · Cancer Gene Therapy · 2015 · 77 citations · Full text

Tumor Regression, Cancer Immunosurveillance, Pd-l1 Expression +9

A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors

Bryant G. Wieking, Daniel W. Vermeer, William C Spanos et al. · Cancer Gene Therapy · 2012 · 55 citations

Vaccination, Non-oncogenic Hpv 16, Vaccine Development +10

Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

Joseph P. Balint, Elizabeth S. Gabitzsch, Adrian Rice et al. · Cancer Immunology Immunotherapy · 2015 · 53 citations · Full text

Phase 1/2, Extended Evaluation, Medicine +9

Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity

Elizabeth S. Gabitzsch, Younong Xu, Lois H. Yoshida et al. · Vaccine · 2009 · 52 citations · Full text

Vaccination, Ad5 Immunity, Novel Adenovirus +11